Adamas Pharmaceuticals (ADMS) Sets New 1-Year Low at $9.03

Share on StockTwits

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares hit a new 52-week low during trading on Thursday . The stock traded as low as $9.03 and last traded at $9.58, with a volume of 25498 shares traded. The stock had previously closed at $10.14.

ADMS has been the subject of several recent analyst reports. HC Wainwright set a $45.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 17th. ValuEngine lowered Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 28th. Mizuho reissued a “buy” rating and set a $75.00 price objective on shares of Adamas Pharmaceuticals in a report on Friday, August 17th. Cowen set a $30.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, November 1st. Finally, Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $32.13.

The company has a market capitalization of $277.18 million, a PE ratio of -2.52 and a beta of 1.43. The company has a quick ratio of 8.74, a current ratio of 8.95 and a debt-to-equity ratio of 1.01.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.34) by $0.12. The business had revenue of $10.61 million during the quarter, compared to analyst estimates of $10.10 million. Adamas Pharmaceuticals had a negative return on equity of 106.74% and a negative net margin of 617.27%. Analysts predict that Adamas Pharmaceuticals Inc will post -5.23 earnings per share for the current fiscal year.

In other news, CEO Gregory T. Went bought 3,850 shares of the business’s stock in a transaction on Wednesday, November 7th. The stock was acquired at an average price of $12.98 per share, with a total value of $49,973.00. Following the completion of the purchase, the chief executive officer now directly owns 182,610 shares in the company, valued at $2,370,277.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alfred G. Merriweather sold 1,665 shares of the company’s stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $19.18, for a total value of $31,934.70. Following the completion of the sale, the chief financial officer now directly owns 25,460 shares of the company’s stock, valued at approximately $488,322.80. The disclosure for this sale can be found here. 24.60% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Pacer Advisors Inc. bought a new stake in Adamas Pharmaceuticals in the third quarter valued at approximately $104,000. Tower Research Capital LLC TRC bought a new stake in Adamas Pharmaceuticals in the third quarter valued at approximately $162,000. Metropolitan Life Insurance Co. NY lifted its position in Adamas Pharmaceuticals by 43.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 7,606 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 2,293 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new stake in Adamas Pharmaceuticals in the second quarter valued at approximately $203,000. Finally, GSA Capital Partners LLP bought a new stake in Adamas Pharmaceuticals in the second quarter valued at approximately $212,000. 94.01% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was published by Zolmax and is the property of of Zolmax. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://zolmax.com/investing/adamas-pharmaceuticals-adms-sets-new-1-year-low-at-9-03/2745652.html.

Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Recommended Story: Compound Interest and Why It Matters When Investing

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Energi  Price Hits $1.21 on Exchanges
Energi Price Hits $1.21 on Exchanges
NuBits Hits Market Capitalization of $437,069.00
NuBits Hits Market Capitalization of $437,069.00
Eaton Vance  Sets New 52-Week Low at $34.55
Eaton Vance Sets New 52-Week Low at $34.55
FCB Financial  Reaches New 12-Month Low at $33.27
FCB Financial Reaches New 12-Month Low at $33.27
Lightpaycoin  24 Hour Volume Hits $83,656.00
Lightpaycoin 24 Hour Volume Hits $83,656.00
Bridge Protocol 1-Day Trading Volume Tops $79.00
Bridge Protocol 1-Day Trading Volume Tops $79.00


Leave a Reply

 
© 2006-2018 Zolmax.